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qdodo@bjmu.edu.Abstract Aminopeptidase N (APN)/CD13 is a transmembrane glycoprotein, which is over-
expressed on tumor neovascular endothelial cells and most tumor cells, where it plays an important
role in tumor angiogenesis. Peptides containing the Asn-Gly-Arg (NGR) motif can speciﬁcally
recognize APN/CD13 allowing them to act as tumor-homing peptides for the targeted delivery of
anti-tumor drugs to tumor neovascular endothelial cells and tumor cells. This article reviews the
literature and recent developments related to APN/CD13, its role in tumor growth and some anti-
tumor drug delivery systems containing NGR peptides designed to target APN/CD13.
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APN/CD13-mediated anti-tumor targeted drug delivery systems 811. Nomenclature and structure of aminopeptidase N
Aminopeptidases are proteinases that catalytically cleave
amino acid residues from the NH2-terminus of polypeptide
chains. Aminopeptidase N (APN) is currently receiving con-
siderable attention because of its participation in tumor
growth, metastasis and immune regulation. APN is a type II
transmembrane glycoprotein containing 967 amino acids with
a molecular mass of 150 kDa.
APN was ﬁrst considered to be a biomarker of normal or
malignant myeloid cell subsets. Later it was found to be
expressed on the surface of a wide variety of cells and organs
of the hematopoietic system. Previously APN was known by
various names including APM, P146, P161 and gp150. In
1988, the International Union of Biochemistry and Molecular
Biology approved the name membrane alanyl aminopeptidase.
In 1989, based on the determination of its amino acid
sequence, APN was found to be identical to the cell surface
differentiation antigen, CD13. Accordingly it is now com-
monly given the abbreviation APN/CD13.
APN/CD13 is a member of the Zn-binding metalloproteinase
superfamily. Its active site contains a Zn2þ ion and its activity is
Zn2þ-dependent. APN/CD13 referentially cleaves an oligopep-
tide segment with a neutral amino acid at the NH2-terminus. Its
activity can be blocked by metalloproteinase inhibitors through
the binding of two monoclonal antibodies to its extracellular
epitope. APN/CD13 is a membrane-bound protein comprising
a short cytoplasmatic N-terminal domain (1–7 amino acid
residues) with unclear function, a single transmembrane domain
(8–29 amino acid residues) existing in an a-helix form, and an
extracellular long and highly glycosylated domain with a 10-N-
type sugar chain and an 11-O-glycan binding site1, which
determines its unique biological functions. APN/CD13 usually
exists as a non-covalently bound homodimer, the dimerization
of which occurs in the endoplasmic reticulum prior to glycosy-
lation in the Golgi complex1.2. Aminopeptidase N and tumor growth
Tumor growth is a complex multi-step process, which includes
tumor cell division, proliferation and angiogenesis. It requires
an energy supply and transportation of metabolic products.
APN/CD13 plays a role in each step of tumor growth
particularly in primary and secondary tumor growth, invasion,
metastasis and angiogenesis.
In order for tumor cells to translocate from their primary
site to distant organs and tissues, they must ﬁrst break through
the basement membrane barrier into the surrounding tissue,
spread with the circulation and ﬁnally implant and grow in
particular parts of the capillary bed. The process of breaking
through the basement membrane barrier depends not only on
the action of various proteinases in the surrounding intersti-
tium but also on the capacity of the tumor cells themselves to
secrete proteinases. In malignant cells, APN/CD13 is generally
evenly distributed on the monolayer cell surface. When cell
cloning takes place, APN/CD13 molecules automatically
migrate to cell–cell contact sites where they degrade extra-
cellular matrix proteins. Thus, inhibiting the activity of APN/
CD13 effectively prevents tumor invasion and metastasis.
When the diameter of a tumor reaches 1–2 mm, nutrients
from the microenvironment can no longer penetrate insufﬁcient amounts to sustain the growth of tumor cells.
Further tumor growth is then dependent on tumor angiogen-
esis in which there is a proliferation of blood vessels that
penetrate into the tumor, supplying nutrients and oxygen and
removing waste products. Angiogenesis is also the ﬁrst step in
tumor metastasis.
APN/CD13 plays an important role in angiogenesis. It is
not expressed in endothelial cells of normal tissues but is
found in malignant and nonmalignant effusions and intratu-
moral ﬂuid2. In addition, its expression in tumor vascular
endothelial cells is signiﬁcantly increased by angiogenic signals
such as hypoxia and growth factors (bFGF, VEGF, TNF-a,
etc.). This indicates that APN/CD13 is a marker of angiogen-
esis. It facilitates the invasion of endothelial cells into
surrounding tissues, enhances the invasiveness of tumor cells
and acts as an auxiliary adhesion factor in cell–cell contact to
enhance cell–cell fusion or act as a receptor in signal
transduction. However, the expression of APN/CD13 is
insufﬁcient to reverse inhibition by Ras of tubular network
formation in endothelial cells in vitro suggesting that APN/
CD13 is mainly involved in the early stages of angiogenesis1.3. Aminopeptidase N mediated anti-tumor drug delivery
systems
After the discovery of RGD peptide, Arap et al.3 used phage
display libraries to isolate peptides that speciﬁcally target
tumor blood vessels. This screen led to peptides containing
the Asn-Gly-Arg (NGR) motif. It appears that a unique form
of APN/CD13, functionally active in mediating NGR binding,
is present in tumor vasculature but not in other APN/CD13-
rich tissues. However, the structural determinants of this
selectivity remain unknown. It has been shown that the
disulﬁde bond in NGR is essential to stabilize the structure
of NGR-containing peptides and thereby enhance the efﬁ-
ciency of tumor targeting4. NGR-containing peptides can be
used as ligands for targeted delivery of chemicals, peptides,
cytokines, liposomes and polymeric micelles to activated blood
vessels in tumors. The therapeutic effects can be improved
while the toxicity and side effects can be reduced. NGR-
containing peptides can also be used for tumor imaging.
Arap et al.3 coupled the peptide Cys-Asn-Gly-Arg-Cys
(CNGRC) to doxorubicin (DXR) and found that human
MDA-MB-435 breast tumor-bearing mice treated with the
conjugate exhibited signiﬁcantly prolonged survival with
reduced toxicity. They also designed short peptides composed
of two functional domains: a tumor blood vessel homing motif
(CNGRC) and a programmed cell death-inducing sequence.
The peptides were designed to directly target angiogenic
endothelial cells, disrupt their mitochondrial membranes and
induce their apoptosis, without affecting other cells. The
peptides showed stronger anti-cancer activity in nude mice
than physical mixtures of peptides composed of the two
functional domains5.
Corti et al. made a signiﬁcant contribution to our knowl-
edge of NGR-containing peptides. They fused murine tumor
necrosis factor (TNF) with CNGRC peptide (NGR-TNF) by
genetic engineering and showed that it was 12–15 times more
efﬁcient than murine TNF in decreasing the tumor burden in
lymphoma and melanoma animal models with no increase in
toxicity. In addition, NGR-TNF made from human TNF
Xun Wang et al.82induced stronger anti-tumor effects than human TNF itself
even at a 30-fold lower dose6. Human NGR-TNF is currently
undergoing a phase II clinical trial7. These researchers also
coupled NGR peptide to the surface of liposomal doxorubicin
(NGR-SL[DXR]) and used it to treat orthotopic neuroblas-
toma (NB) xenografts in severe combined immunodeﬁcient
(SCID) mice. Pharmacokinetic studies indicated that the
liposomes remained in blood for a long time. Uptake of
NGR-SL[DXR] into NB tumor cells was at least 10 times
higher than that of non-targeted SL[DXR] liposomes after
24 h. Histopathological analysis revealed pronounced destruc-
tion of the tumor vasculature with a marked decrease in vessel
density and increased tumor cell apoptosis. Mice injected with
NGR-SL[DXR] displayed rapid tumor regression as well as
inhibition of metastatic growths. In contrast, mice treated with
mismatched ARA-modiﬁed SL[DXR] peptide formed large
well-vascularized tumors8.
Corti et al. also prepared sterically stabilized immunolipo-
somes (SIL) loaded with DXR and modiﬁed with a monoanti-
body targeted to the disialoganglioside receptor GD2 [aGD2-
SIL(DXR)]. They observed an additive anti-tumor effect of
the combination of NGR-SL(DXR) (targeting tumor endothe-
lial cells) and aGD2-SIL(DXR) (targeting neuroblastoma
cells). A signiﬁcant improvement in anti-tumor effects was
seen in neuroblastoma-bearing animal models when treated
with the combined formulation compared with control mice or
mice treated with either tumor- or vascular-targeted liposomal
formulations alone. The combined treatment resulted in a
dramatic inhibition of tumor endothelial cell density. Long-
term survival occurred only in animals treated with the
combined formulation. The fact that the dual-targeting strat-
egy of combining tumor targeting and tumor endothedial
targeting was more effective and less toxic suggests that it has
a promising future in cancer chemotherapy9.
Chen et al.10 designed PEGylated liposome-polycation-
DNA (LPD-PEG) nanoparticles for efﬁcient delivery of small
interfering RNA (siRNA) to solid tumors in mice by mod-
iﬁcation with NGR peptide. LPD-PEG-NGR efﬁciently deliv-
ered siRNA to the cytoplasm and down regulated the target
gene in CD13(þ) HT1080 cells but not CD13() HT-29 cells.
In contrast, nanoparticles containing a control peptide, LPD-
PEG-ARA, produced only little siRNA uptake and gene
silencing activity. LPD-PEG-NGR also efﬁciently inhibited
HT1080 xenograft tumor growth in vivo.
Son et al.11 synthesized a multifunctional polymer based on
low molecular weight branched polyethylenimine (BPEI)
thiolated with propylene sulﬁde and mixed it with alpha-
maleimide-omega-N-hydroxysuccinimide ester polyethylene
glycol (MAL-PEG-NHS, MW: 5000) and cyclic NGR
(cNGR) peptide. Besides achieving efﬁcient release of pDNA
and long duration, the multifunctional gene carrier achieved
efﬁcient tumor targeting using the cNGR peptide. Cellular
uptake of polymers was evaluated by confocal laser scanning
microscopy (CLSM). CD13(þ)B16F1 cells showed enhanced
uptake of pDNA compared with CD13() MDA-MB-
231 cells.
In our laboratory, the anti-tumor efﬁcacy of PEG-b-PLA
polymeric micelles (NGR-PM) decorated on their surface with
NGR peptide was evaluated12. HT1080 cells (with high
expression of CD13) were chosen as the model of positive
tumor cells and HUVEC (with intermediate expression of
CD13) as the model of tumor endothelial cells. The resultsshowed that actively targeted PM produced stronger adhesion
and better uptake than undecorated PM. HT1080 cells were
also able to take up NGR-PM-DTX to a larger extent than
HUVEC. After the PM was loaded with DTX, NGR-PM-
DTX was found to be more cytotoxic than PM-DTX to
HT1080 cells. NGR-PM-DTX also showed greater ability to
inhibit the proliferation of HUVEC. In BALB/c mice bearing
HT1080 tumor xenografts, stronger anti-tumor efﬁcacy and
less change in body weight were observed in the NGR-PM-
DTX group with good in vitro–in vivo correlation12.
Our research group also prepared NGR-modiﬁed DSPE-
PEG micelles containing paclitaxel (PTX)13. These NGR-M-
PTX micelles signiﬁcantly depressed the proliferation of
murine brain microvascular endothelial cells (BMEC)
in vitro. The anti-tumor activity of NGR-M-PTX was also
evident in C6 glioma tumor-bearing rats in vivo where glioma
tumor growth was markedly inhibited compared with Taxol.
The results demonstrate the antiangiogenic efﬁcacy of NGR-
M-PTX.
Oostendorp et al.14 developed cNGR-labeled paramagnetic
quantum dots (cNGR-pQDs) for the noninvasive assessment
of tumor angiogenic activity using quantitative in vivo mole-
cular magnetic resonance imaging (MRI). MRI results were
validated using ex vivo two-photon laser scanning microscopy
(TPLSM). The results showed that cNGR-pQDs were primar-
ily located on the surface of tumor endothelial cells and to a
lesser extent in the vessel lumen, supporting a high speciﬁcity
of cNGR-pQDs for angiogenic tumor vasculature.4. Future of aminopeptidase N mediated anti-tumor drug
delivery systems
Aminopeptidase N/CD13-mediated anti-tumor targeted drug
delivery systems show great promise in preclinical studies, and,
as a result, NGR-containing peptides targeting APN/CD13
are receiving increasing attention. However, additional
research is required to identify their mechanisms of action15.
With more intensive research into therapeutic strategies, more
small-molecule drugs, biological macromolecule drugs and
some kinds of carriers are combined with NGR-containing
peptide to produce a variety of novel tumor targeted drug
delivery systems. NGR-containing peptides targeting APN/
CD13 may also lead to improvements in tumor diagnosis and
tumor blood vessel imaging.Acknowledgments
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